Pharmaceutical Sector Faces Tough Times with Mixed Results as CDMO Recovers

This winter has felt exceptionally long for the pharmaceutical industry. Since the summer of 2021, few anticipated that the downturn would extend beyond three and a half years, leading even the most patient investors to the brink of despair.

As the CDMO sector begins to show signs of recovery, companies like WuXi AppTec have seen impressive rebounds—approximately 60% for WuXi PharmaTech and 110% for WuXi Biologics, with WuXi AppTec approaching historical highs. While a dramatic turnaround may not be in sight, even slight improvements could lead to significant elasticity in the market.

In Q4 2024, public mutual funds' holdings in the pharmaceutical sector dropped to 8.58%, a 1.08 percentage point decline, hitting a historical low. This suggests that any minor influx of capital could yield substantial effects.

The thawing of this prolonged winter is evident. On the payment side, a diversified payment system is expected to emerge, moving away from a single-payment structure. This change, alongside growing public concern over drug efficacy, may shift collective purchasing and insurance negotiations toward a balance of cost control and quality assurance. Additionally, the IPO market for unprofitable biotech firms might reopen, triggering a positive chain reaction.

The spring for serious medical needs seems imminent, though consumer healthcare continues to face challenges. Traditional Chinese medicine is likened to the vaccines of three years ago, with the cold spell possibly just beginning.

As of January 31, 278 pharmaceutical companies have released their 2024 earnings forecasts, with around 41% reporting positive net profit growth, while 59% anticipate declines. In the midst of widespread despair, the few companies achieving double-digit growth deserve recognition.

The coming year marks a pivotal moment for both payment and financing avenues. The initial version of the Category B insurance directory is planned for release this year, signaling the formal establishment of an ecosystem for innovative drug payments. While changes may seem minor, they represent a significant beginning.

Key developments include the long-awaited support for innovative drugs through commercial insurance, allowing these medications to enter the market more rapidly. The introduction of market-driven pricing for innovative drugs will also empower insurance companies, shifting the dynamic from a solely government-controlled system.

The public's increasing focus on the efficacy of domestic drugs will not fade away with the upcoming Spring Festival. The prevailing sentiment is clear—price should not be the sole consideration. This perspective could lead to marginal improvements in future negotiations.

The signs of thawing in financing for unprofitable biotech firms are also evident. On February 7, Dizhe Pharmaceuticals secured approval for an 18.5 billion yuan fundraising plan, marking the first unprofitable company to receive regulatory approval since the “Eight Regulations” initiative.

As the capital market stabilizes, China’s innovative pharmaceuticals may see a rise in external business development prices as cash flow improves.